Overview
Cagrilintide is an investigational long-acting analog of amylin (islet amyloid polypeptide), a hormone co-secreted with insulin by pancreatic beta cells. The native peptide is prone to aggregation and has a short half-life; cagrilintide is engineered with stabilizing modifications and fatty-acid acylation to enable once-weekly dosing in research settings. It represents the amylin-analog approach to appetite and weight regulation, a mechanism distinct from the incretin class.
Research interest focuses on amylin agonism as a complementary lever to GLP-1 signaling, particularly in combination regimens being explored for weight management.
Mechanism of action
Cagrilintide acts as a non-selective agonist at amylin and calcitonin receptors. Amylin signaling slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety through actions in the area postrema and other hindbrain regions, reducing food intake.
Because its mechanism is complementary to and distinct from GLP-1 receptor agonism, research has explored whether combining amylin and incretin agonism produces additive effects on satiety and body weight. The acylation and structural stabilization extend the half-life relative to native amylin, supporting infrequent dosing in study protocols.
Research findings
- Investigated in phase 1 and phase 2 trials for body-weight reduction in adults with obesity.
- Studied as monotherapy and, prominently, in fixed-combination research with the GLP-1 receptor agonist semaglutide.
- Examined for effects on appetite, satiety, and food intake.
- Investigated for glycemic and metabolic parameters in combination regimens.
- Dose-ranging research has explored tolerability and efficacy across study doses.
Research context
Reported pharmacokinetics indicate a half-life of roughly one week, supporting once-weekly schedules used in trials. As an investigational agent, published dosing ranges and titration frequencies vary by study and are described at a high level only, often escalated gradually to manage tolerability; specifics differ by trial. No regimen, concentration, or preparation information is provided here. This is a research reference only. These compounds are not approved for human use outside of regulated clinical settings; consult the primary literature.
Handling & storage
In laboratory settings, the lyophilized peptide is generally stored frozen (commonly -20°C or colder) and protected from light and moisture. Reconstituted solutions of peptides in this class are typically refrigerated at 2-8°C and reported to have limited stability. Amylin-class peptides can be aggregation-prone, so freeze-thaw cycling and agitation are generally minimized. No concentration or preparation guidance is provided.
Reported safety signals
Reported adverse effects in research are largely gastrointestinal, including nausea and reduced appetite, generally most prominent early in dosing. Injection-site reactions have also been reported. As an investigational compound, its long-term safety profile is not established, and tolerability data continue to accrue from ongoing studies, particularly in combination with incretin agents.
Studied alongside
Cagrilintide is most prominently studied alongside the GLP-1 receptor agonist semaglutide as a combination approach to weight management. It is also discussed in the broader context of incretin agents such as tirzepatide and the triple agonist retatrutide, where amylin agonism represents a complementary, non-incretin mechanism.
At a glance
Research strengths
- Distinct amylin mechanism complementary to incretin agonists
- Long half-life supports once-weekly study schedules
- Studied in combination regimens for additive satiety effects
- Active investigational target in weight-management research
Limitations & cautions
- Investigational — not approved, long-term safety unestablished
- Gastrointestinal adverse effects reported
- Amylin-class peptides can be aggregation-prone in handling
- Most data come from combination rather than monotherapy studies
